Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15807161rdf:typepubmed:Citationlld:pubmed
pubmed-article:15807161lifeskim:mentionsumls-concept:C0220847lld:lifeskim
pubmed-article:15807161lifeskim:mentionsumls-concept:C0019682lld:lifeskim
pubmed-article:15807161lifeskim:mentionsumls-concept:C0019699lld:lifeskim
pubmed-article:15807161pubmed:dateCreated2005-4-5lld:pubmed
pubmed-article:15807161pubmed:abstractTextCoexisting HIV and HCV infection involves approx. 10 million people in the world. It is most common in drug addicts taking drug injections as well as in haemophiliacs. In the research we have confronted the existing views on natural history progression in hepatitis C in HIV infected, with our own study. The existing recommendations for hepatitis C treatment have also been presented. It was pointed out that there is a possibility of interaction between the drugs applied in the treatment and the antiretrovirus therapy and what is connected with it, the possibility of potentially adverse actions. It was also shown that early treatment of hepatitis C in HIV infected slows down the progress of liver fibrosis, prevents liver failure, improves HA-Art tolerance, increases immunological reconstruction and improves the quality of the patients' lives.lld:pubmed
pubmed-article:15807161pubmed:languagepollld:pubmed
pubmed-article:15807161pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15807161pubmed:citationSubsetIMlld:pubmed
pubmed-article:15807161pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15807161pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15807161pubmed:statusMEDLINElld:pubmed
pubmed-article:15807161pubmed:issn0033-2100lld:pubmed
pubmed-article:15807161pubmed:authorpubmed-author:HalotaWaldema...lld:pubmed
pubmed-article:15807161pubmed:authorpubmed-author:Paw?owskaMa?g...lld:pubmed
pubmed-article:15807161pubmed:authorpubmed-author:GrabczewskaEd...lld:pubmed
pubmed-article:15807161pubmed:issnTypePrintlld:pubmed
pubmed-article:15807161pubmed:volume58 Suppl 1lld:pubmed
pubmed-article:15807161pubmed:ownerNLMlld:pubmed
pubmed-article:15807161pubmed:authorsCompleteYlld:pubmed
pubmed-article:15807161pubmed:pagination71-5lld:pubmed
pubmed-article:15807161pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15807161pubmed:meshHeadingpubmed-meshheading:15807161...lld:pubmed
pubmed-article:15807161pubmed:meshHeadingpubmed-meshheading:15807161...lld:pubmed
pubmed-article:15807161pubmed:meshHeadingpubmed-meshheading:15807161...lld:pubmed
pubmed-article:15807161pubmed:meshHeadingpubmed-meshheading:15807161...lld:pubmed
pubmed-article:15807161pubmed:meshHeadingpubmed-meshheading:15807161...lld:pubmed
pubmed-article:15807161pubmed:meshHeadingpubmed-meshheading:15807161...lld:pubmed
pubmed-article:15807161pubmed:meshHeadingpubmed-meshheading:15807161...lld:pubmed
pubmed-article:15807161pubmed:meshHeadingpubmed-meshheading:15807161...lld:pubmed
pubmed-article:15807161pubmed:meshHeadingpubmed-meshheading:15807161...lld:pubmed
pubmed-article:15807161pubmed:meshHeadingpubmed-meshheading:15807161...lld:pubmed
pubmed-article:15807161pubmed:year2004lld:pubmed
pubmed-article:15807161pubmed:articleTitle[HIV and HCV infections--clinical implications].lld:pubmed
pubmed-article:15807161pubmed:affiliationKatedra i Klinika Chorób Zaka?nych i Hepatologii Akademii Medycznej im LRydygiera w Bydgoszczy.lld:pubmed
pubmed-article:15807161pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15807161pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:15807161pubmed:publicationTypeReviewlld:pubmed